Riluzole in Fragile X Syndrome

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the effectiveness and tolerability of riluzole in adults with Fragile X Syndrome.

Clinical Trial Description

Fragile X Syndrome (FXS) represents the most common inherited form of intellectual disability. FXS is more common in males and the symptoms associated with the disorder are more marked in males. FXS is associated with characteristic physical features, behaviors, and comorbidities. Those with FXS often suffer from behavioral difficulties that include anxiety-related symptoms (shyness, social phobia, obsessive-compulsive disorder (OCD) symptoms), attention deficit hyperactivity symptoms (overarousal, hyperactivity, distractibility, impulsivity) and aggressive/self-injurious behaviors.

Riluzole is approved by the FDA for use in treating amyotrophic lateral sclerosis (ALS) in adults. Recently, riluzole has been the subject of several open-label studies describing the use of the drug in treatment-resistant depression and OCD.

Given the overlap between repetitive behavior in FXS and symptoms of OCD, it is logical to study riluzole in FXS given the compound's promise in ameliorating treatment-refractory symptoms of OCD. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00895752
Study type	Interventional
Source	Indiana University
Contact
Status	Completed
Phase	Phase 4
Start date	April 2009
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05418049` - Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge	Phase 2
Enrolling by invitation	`NCT01364818` - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment	N/A
Completed	`NCT01120626` - Randomized Controlled Study of Donepezil in Fragile X Syndrome	Phase 2
Completed	`NCT00965432` - A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107	Phase 1
Completed	`NCT01204151` - Teaching Math Skills to Individuals With Fragile X Syndrome	N/A
Active, not recruiting	`NCT00334971` - Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women	N/A
Enrolling by invitation	`NCT06139172` - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities	N/A
Recruiting	`NCT04977986` - Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome	Phase 3
Active, not recruiting	`NCT04698551` - NIPD on cffDNA for Triplet Repeat Diseases
Completed	`NCT03722290` - Metformin in Children and Adults With Fragile X Syndrome	Phase 2
Completed	`NCT05030129` - Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome	Phase 2
Recruiting	`NCT05957549` - Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG	N/A
Recruiting	`NCT04141163` - Metformin in Patients With Fragile X	Phase 1/Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Completed	`NCT00858689` - Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome	N/A
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Enrolling by invitation	`NCT03802799` - Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS	Phase 2/Phase 3
Recruiting	`NCT05295277` - Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
Enrolling by invitation	`NCT03836300` - Parent and Infant Inter(X)Action Intervention (PIXI)	N/A
Completed	`NCT01725152` - Ganaxolone Treatment in Children With Fragile X Syndrome	Phase 2